骨形成蛋白2在脑胶质瘤中的表达及其在预后评估中的应用价值分析  

Expression of bone morphogenetic protein 2 and its role in prognosis evaluation in gliomas

作　　者：周开甲[1] 刘彦伟[2] 赵征 张鸣[1] 刘伯伟[1] 郑宗清[1] Zhou Kaijia;Liu Yanwei;Zhao Zheng;Zhang Ming;Liu Bowei;Zheng Zongqing(Department of Neuro-Oncology Surgery,Fujian Cancer Hospital Affiliated to Fujian Medical University,Cancer Hospital of Fujian Province,Fuzhou 350014,China;Beijing Neurosurgical Institute,Capital Medical University,Beijing 100070,China)

机构地区：[1]福建省肿瘤医院,福建医科大学附属肿瘤医院神经肿瘤外科,福州350014 [2]首都医科大学北京神经外科研究所,北京100070

出　　处：《中华神经医学杂志》2020年第7期663-670,共8页Chinese Journal of Neuromedicine

摘　　要：目的分析骨形成蛋白2(BMP2)mRNA在不同类型胶质瘤中的表达及其与生存期的关系,明确其作为胶质瘤预后评估指标的应用价值。方法收集中国胶质瘤基因组图谱(CGGA)数据库中692例脑胶质瘤患者资料,比较不同组织病理类型、不同性别、年龄、原发或复发状态胶质瘤患者及不同WHO分级、异柠檬酸脱氢酶1(IDH1)突变、1p19q杂合性缺失状态、分子分级胶质瘤患者中BMP2 mRNA表达差异,以及不同分类胶质瘤患者中BMP2 mRNA高表达量患者与低表达量患者生存期的差异。结果(1)不同组织病理类型胶质瘤中mRNA表达不同,差异有统计学意义(P=9.392,P=0.000)。少突胶质瘤亚型mRNA表达最高,其次是星形细胞瘤亚型,胶质母细胞瘤中最低。男性患者与女性患者间BMP2 mRNA相对表达量分别为9.78±0.65、11.26±0.86,差异无统计学意义<43岁组及≥43岁组患者mRNA相对表达量分别为12.51±0.81、8.37±0.65,差异有统计学意义(P<0.05)。原发与复发胶质瘤患者BMP2 mRNA相对表达量分别为10.09±0.62、10.90±0.93,差异无统计学意义(P>0.05)。WHO Ⅱ~Ⅳ级胶质瘤患者及BMP2 mRNA相对表达量分别为13.98±1.12、12.88±0.88、5.18±0.64,差异有统计学意义(P=30.912,P=0.000)。IDH1野生型与突变型患者间mRNA相对表达量分别为2.73±0.16、17.47±0.85,差异有统计学意义(P<0.05)。1p/19q无缺失与1p/19q缺失患者间相对表达量分别为7.02±0.36、25.28±1.66,差异有统计学意义(P<0.05)。较低级别胶质瘤患者及胶质瘤母细胞瘤患者中IDH1突变型患者mRNA表达量均高于IDH1野生型患者,差异有统计学意义(P<0.05)。(2)原发胶质瘤患者及复发胶质瘤患者中,BMP2 mRNA高表达(≥4.68)患者生存期均明显长于低表达(<4.68)患者,差异有统计学意义(χ^2=62.975,P=0.000;χ^2=12.810,P=0.000)。结论mRNA表达量可以作为预测胶质瘤恶性程度的指标,高表达者患者生存期更长。Objective To study the mRNA expressions of bone morphogenetic protein 2(BMP2)in different types of gliomas and the relation between BMP2 mRNA expression and survival time,and to explore the role of BMP2 mRNA expression in prognosis evaluation in gliomas.Methods The clinical data of 692 patients with gliomas in China Glioma Genome Atlas(CGGA)database were collected.Differences of BMP2 mRNA expression were compared among glioma patients with different histophiologic types,and patients with different gender and different ages,patients at primary or recurrent status,and those with different WHO grading,isocitrate dehydrogenase 1(IDH1)mutation,1P19q heterozygous deletion status,and molecular typing.The difference in survival time between patients with high and low BMP2 mRNA expression levels were compared in different categories of gliomas.Results(1)The BMP2 mRNA expressions were different in different histopathological types of gliomas(F=9.392,P=0.000);BMP2 expression in the oligodendroglioma subtype was the highest,followed by astrocytoma subtype and glioblastoma.The BMP2 relative mRNA expressions in male and female patients were 9.78±0.65 and 11.26±0.86,respectively,without statistical difference(P>0.05).The BMP2 relative mRNA expressions in patients<43 years old and patients≥43 years old were 12.51±0.81 and 8.37±0.65,respectively,with significant difference(P<0.05).The BMP2 relative mRNA expressions were 10.09±0.62 and 10.90±0.93,respectively,without signiJBcant difference(P>0.05).The BMP2 relative mRNA expressions were 13.98±1.12,12.88±0.88 and 5.18±0.64 in WHO grading Ⅱ,Ⅲ,and Ⅳ gliomas patients,respectively,with significant differences(F=30.912,P=0.000).The BMP2 relative mRNA expressions in patients with IDH1 wild-type and IDH1 mutant were 2.73±0.16 and 17.47±0.85,respectively,with significant difference(P<0.05).The BMP2 relative mRNA expressions in patients with 1P/19Q non-absence and 1P/19Q absence were 7.02±0.36 and 25.28±1.66,respectively,with significant difference(P<0.05).In patients w

关 键 词：神经胶质瘤 骨形成蛋白2 分子分型 信号通路 

分 类 号：R739.4[医药卫生—肿瘤]